{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:30Z","timestamp":1793228250637,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jdin.2024.06.006","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T23:47:10Z","timestamp":1723852030000},"page":"71-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["The role of interleukin-17 and interleukin-23 inhibitors in the development, progression, and recurrence of cancer: A systematic review"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5140-2007","authenticated-orcid":false,"given":"Marie","family":"Vangilbergen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Stockman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axelle","family":"Van De Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Garmyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Punie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Hillary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jdin.2024.06.006_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/exd.13676","article-title":"Inhibition of interleukin-12 and\/or interleukin-23 for the treatment of psoriasis: what is the evidence for an effect on malignancy?","volume":"27","author":"Ergen","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jdin.2024.06.006_bib2","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.jdin.2024.06.006_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028116","article-title":"Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort","volume":"9","author":"Egeberg","year":"2019","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.jdin.2024.06.006_bib4","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/jdv.15762","article-title":"Incidence and prevalence of psoriasis in Israel between 2011 and 2017","volume":"33","author":"Schonmann","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7551","key":"10.1016\/j.jdin.2024.06.006_bib5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jdin.2024.06.006_bib6","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/carcin\/bgu017","article-title":"IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway","volume":"35","author":"Zhang","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jdin.2024.06.006_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113928","article-title":"New insights into the IL-12 and IL-23: from a molecular basis to clinical application in immune-mediated inflammation and cancers","volume":"175","author":"Chyuan","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jdin.2024.06.006_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2018.12.002","article-title":"IL-23 in inflammatory bowel diseases and colon cancer","volume":"45","author":"Neurath","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jdin.2024.06.006_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/JIR.S165330","article-title":"Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives","volume":"11","author":"Rawla","year":"2018","journal-title":"J Inflamm Res"},{"issue":"1","key":"10.1016\/j.jdin.2024.06.006_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: a systematic review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdin.2024.06.006_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108402","article-title":"The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases","volume":"102","author":"Berry","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"10275","key":"10.1016\/j.jdin.2024.06.006_bib12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jdin.2024.06.006_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cyto.2015.09.011","article-title":"Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis","volume":"89","author":"Qian","year":"2017","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.jdin.2024.06.006_bib14","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1007\/s13277-014-1890-4","article-title":"Significant association between interleukin-17A polymorphism and colorectal cancer","volume":"35","author":"Omrane","year":"2014","journal-title":"Tumour Biol"},{"issue":"7","key":"10.1016\/j.jdin.2024.06.006_bib15","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00262-010-0849-6","article-title":"Th17 cells: positive or negative role in tumor?","volume":"59","author":"Ji","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.jdin.2024.06.006_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ajpath.2012.08.041","article-title":"The role and regulation of human Th17 cells in tumor immunity","volume":"182","author":"Ye","year":"2013","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.jdin.2024.06.006_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032126","article-title":"IL-17 mediated inflammation promotes tumor growth and progression in the skin","volume":"7","author":"He","year":"2012","journal-title":"PLoS One"},{"issue":"7101","key":"10.1016\/j.jdin.2024.06.006_bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature04808","article-title":"IL-23 promotes tumour incidence and growth","volume":"442","author":"Langowski","year":"2006","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jdin.2024.06.006_bib19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4049\/jimmunol.171.2.600","article-title":"Antitumor and antimetastatic activity of IL-23","volume":"171","author":"Lo","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.jdin.2024.06.006_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fimmu.2014.00116","article-title":"Autoimmunity as a double agent in tumor killing and cancer promotion","volume":"5","author":"Toomer","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.jdin.2024.06.006_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-3-030-55617-4_6","article-title":"IL-23 and the tumor microenvironment","volume":"1290","author":"Subhadarshani","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jdin.2024.06.006_bib22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0065-230X(08)00407-7","article-title":"IFN inducibility of major histocompatibility antigens in tumors","volume":"101","author":"Seliger","year":"2008","journal-title":"Adv Cancer Res"},{"issue":"14","key":"10.1016\/j.jdin.2024.06.006_bib23","doi-asserted-by":"crossref","first-page":"7695","DOI":"10.3390\/ijms22147695","article-title":"STAT1 is required for decreasing accumulation of granulocytic cells via IL-17 during initial steps of colitis-associated cancer","volume":"22","author":"Delgado-ramirez","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.jdin.2024.06.006_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1361088","article-title":"STAT1 gene deficient mice develop accelerated breast cancer growth and metastasis which is reduced by IL-17 blockade","volume":"6","author":"Varikuti","year":"2017","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.jdin.2024.06.006_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.imbio.2014.09.002","article-title":"Therapeutic efficacy of IL-17A antibody injection in preventing the development of colitis associated carcinogenesis in mice","volume":"220","author":"Qi","year":"2015","journal-title":"Immunobiology"},{"issue":"6","key":"10.1016\/j.jdin.2024.06.006_bib26","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1158\/0008-5472.CAN-10-3994","article-title":"Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases","volume":"71","author":"Teng","year":"2011","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jdin.2024.06.006_bib27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12885-021-08969-0","article-title":"Variable roles of interleukin-17F in different cancers","volume":"22","author":"Mikkola","year":"2022","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.jdin.2024.06.006_bib28","first-page":"1","article-title":"Environmental factors inducing human cancers","volume":"41","author":"Parsa","year":"2012","journal-title":"Iran J Public Health"},{"issue":"21","key":"10.1016\/j.jdin.2024.06.006_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijerph17218089","article-title":"Impact of gene\u2013environment interactions on cancer development","volume":"17","author":"Mbemi","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jdin.2024.06.006_bib30","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejca.2021.07.039","article-title":"The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers","volume":"157","author":"Dyba","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jdin.2024.06.006_bib31","first-page":"1","article-title":"The incidence and clinical analysis of non-melanoma skin cancer","volume":"11","author":"Ci\u0105\u017cy\u0144ska","year":"2021","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.jdin.2024.06.006_bib32","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/jdv.16683","article-title":"Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2)","volume":"34","author":"Lambert","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.jdin.2024.06.006_bib33","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/jdv.14314","article-title":"Adverse events associated with discontinuation of the biologics\/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm","volume":"31","author":"Belinch\u00f3n","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jdin.2024.06.006_bib34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s13555-022-00693-2","article-title":"Biologic therapy for moderate to severe psoriasis. Real-world follow-up of patients who initiated biologic therapy at least 10 years ago","volume":"12","author":"Elberd\u00edn","year":"2022","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jdin.2024.06.006_bib35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/jdv.14145","article-title":"Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study","volume":"31","author":"Esposito","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jdin.2024.06.006_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10689-021-00250-4","article-title":"Malignancy risk in individuals with familial adenomatous polyposis receiving biologics and immunomodulators","volume":"21","author":"Faisal","year":"2022","journal-title":"Fam Cancer"},{"issue":"4","key":"10.1016\/j.jdin.2024.06.006_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12476","article-title":"Risk of malignancy in psoriatic patients: our clinical experience","volume":"30","author":"Magnano","year":"2017","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.jdin.2024.06.006_bib38","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2024.06.006_bib39","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn's disease: the IM-UNITI trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jdin.2024.06.006_bib40","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jaad.2016.10.033","article-title":"Biologic drug survival in Israeli psoriasis patients","volume":"76","author":"Shalom","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jdin.2024.06.006_bib41","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1468-3083.2011.04180.x","article-title":"Management of moderate to severe psoriasis with systemic immunomodulatory therapies: a 5-year experience from two departments of dermatology of Northern France","volume":"26","author":"Staumont-Sall\u00e9","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jdin.2024.06.006_bib42","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1468-3083.2011.04044.x","article-title":"Safety of treatment with biologics for psoriasis in daily practice: 5-year data","volume":"26","author":"Van L\u00fcmig","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jdin.2024.06.006_bib43","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.gtc.2014.05.010","article-title":"The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease","volume":"43","author":"Dulai","year":"2014","journal-title":"Gastroenterol Clin North Am"},{"issue":"2","key":"10.1016\/j.jdin.2024.06.006_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09546634.2020.1782817","article-title":"Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1","volume":"33","author":"Griffiths","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.jdin.2024.06.006_bib45","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaad.2020.09.047","article-title":"Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)","volume":"84","author":"Lebwohl","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2024.06.006_bib46","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bjd.20595","article-title":"Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up","volume":"185","author":"Papp","year":"2021","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2024.06.006_bib47","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jaad.2018.03.047","article-title":"Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis","volume":"79","author":"Zachariae","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2024.06.006_bib48","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s13555-019-00340-3","article-title":"Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure","volume":"10","author":"Armstrong","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"10.1016\/j.jdin.2024.06.006_bib49","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13075-020-2099-0","article-title":"Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis","volume":"22","author":"Combe","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.jdin.2024.06.006_bib50","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2016.09.026","article-title":"Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data","volume":"76","author":"Strober","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jdin.2024.06.006_bib51","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jdin.2024.06.006_bib52","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjd.20136","article-title":"The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up","volume":"185","author":"Lebwohl","year":"2021","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2024.06.006_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14889","article-title":"IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: a case series with systematic literature review","volume":"34","author":"Bellinato","year":"2021","journal-title":"Dermatol Ther"},{"issue":"20","key":"10.1016\/j.jdin.2024.06.006_bib54","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMc1703047","article-title":"Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade","volume":"376","author":"Esfahani","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jdin.2024.06.006_bib55","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266632872400110X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266632872400110X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T19:42:17Z","timestamp":1748547737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266632872400110X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":55,"alternative-id":["S266632872400110X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2024.06.006","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of interleukin-17 and interleukin-23 inhibitors in the development, progression, and recurrence of cancer: A systematic review","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2024.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}